drugset / Trial / NCT02785250
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
Phase 1/2
Unknown
85 enrolled
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Incyte Corporation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
T cell activating therapy DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the safety and potential immune-modulating activity of the combination of these agents.
Timeline
- Start
- 2016-04
- Primary completion
- 2020-10
- Completion
- 2025-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epacadostat | Small molecule | — | Oral |
| Background | Cyclophosphamide | Other / unclassified | — | Oral |